11
ALL11
AinosYear
11
ALL6
20243
20232
2022DEALS // DEV.
11
ALL4
Deals7
DevelopmentsCountry
10
ALL1
TAIWAN9
U.S.A11
ALL1
Lind Partners1
Merdury Pharmaceutical7
Not Applicable1
Taiwan Tanabe Seiyaku1
UndisclosedTherapeutic Area
11
ALL2
Hematology1
Immunology6
Infections and Infectious Diseases2
OncologyStudy Phase
11
ALL3
Approved1
Phase III5
Phase II2
Phase IDeal Type
4
ALL1
Agreement2
Financing1
PartnershipProduct Type
11
ALL11
Large moleculeDosage Form
7
ALL7
Troche/LozengeLead Product
11
ALL11
Interferon AlfaTarget
0
ALLLead Product(s) : Interferon Alfa
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Taiwan Tanabe Seiyaku
Deal Size : Undisclosed
Deal Type : Partnership
US-Taiwan Partnership to Advance Manufacturing of Sjögren's Syndrome Drug
Details : The partnership between Ainos and Taiwan Tanabe Seiyaku aims to accelerate the global market launch of Veldona (Interferon Alfa) for the treatment of Sjögren's syndrome.
Product Name : Undisclosed
Product Type : Large molecule
Upfront Cash : Undisclosed
December 02, 2024
Lead Product(s) : Interferon Alfa
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Taiwan Tanabe Seiyaku
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Interferon Alfa
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Ainos Announces IRB Approval for Sjögren’s Syndrome Clinical Study
Details : Veldona (interferon alfa) binds to type I interferon receptors (IFNAR). It is being evaluated as a potential treatment for patients with Sjögren's syndrome.
Product Name : Veldona
Product Type : Large molecule
Upfront Cash : Not Applicable
November 11, 2024
Lead Product(s) : Interferon Alfa
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Interferon Alfa
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Ainos Plans Taiwan Study for VELDONA in HIV-Related Oral Warts
Details : Veldona (interferon alfa) binds to type I interferon receptors (IFNAR). It is being evaluated as a potential treatment for oral warts in HIV-seropositive patients.
Product Name : Veldona
Product Type : Large molecule
Upfront Cash : Not Applicable
September 17, 2024
Lead Product(s) : Interferon Alfa
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Interferon Alfa
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : $9.0 million
Deal Type : Financing
Ainos Raises $9 Million in Growth Capital with Existing Shareholder
Details : The financing will be used to advance company's products including VELDONA (interferon alfa) which binds to type I interferon receptors (IFNAR). It is being evaluated for thrombocytopenia.
Product Name : Veldona
Product Type : Large molecule
Upfront Cash : Undisclosed
May 07, 2024
Lead Product(s) : Interferon Alfa
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : $9.0 million
Deal Type : Financing
Lead Product(s) : Interferon Alfa
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Ainos Submits Clinical Hold Response to FDA for VELDONA Trial Against Mild COVID-19
Details : Veldona (interferon alfa) binds to type I interferon receptors (IFNAR). It is being evaluated in phase 1 clinial trials for the treatment of mild COVID-19 symptoms.
Product Name : Veldona
Product Type : Large molecule
Upfront Cash : Not Applicable
February 05, 2024
Lead Product(s) : Interferon Alfa
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Interferon Alfa
Therapeutic Area : Hematology
Study Phase : IND Enabling
Sponsor : Lind Partners
Deal Size : $1.7 million
Deal Type : Financing
Ainos Announces $1.75 Million Follow-On Funding
Details : Veldona (interferon alfa) is progressing towards IND applications for human drug candidates and co-development of VOC sensing tech using AI Nose.
Product Name : Veldona
Product Type : Large molecule
Upfront Cash : Undisclosed
January 24, 2024
Lead Product(s) : Interferon Alfa
Therapeutic Area : Hematology
Highest Development Status : IND Enabling
Sponsor : Lind Partners
Deal Size : $1.7 million
Deal Type : Financing
Details : Veldona (interferon alfa) binds to type I interferon receptors (IFNAR). It is being evaluated as a potential treatment for oral warts in HIV-seropositive patients.
Product Name : Veldona
Product Type : Large molecule
Upfront Cash : Not Applicable
November 21, 2023
Lead Product(s) : Interferon Alfa
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Veldona is a low-dose oral interferon formulation investigated as a potential treatment for oral warts in HIV-seropositive patients. Ainos plans to pursue a pre-IND meeting with the U.S. FDA in advance of planned Phase III clinical studies for the drug c...
Product Name : Veldona
Product Type : Large molecule
Upfront Cash : Not Applicable
September 18, 2023
Lead Product(s) : Interferon Alfa
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Interferon Alfa
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Merdury Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Ainos and Merdury will evaluate the feasibility of Merdury's potential investment and participation in the completion of a Phase 3 clinical trial of the Company's Veldona (interferon alfa) drug candidate for treatment of oral warts i...
Product Name : Veldona
Product Type : Large molecule
Upfront Cash : Undisclosed
March 14, 2023
Lead Product(s) : Interferon Alfa
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Merdury Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Interferon Alfa
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Veldona, a low-dose oral interferon-alpha formulation to boost the human body’s frontline defenses against disease and infection. IFN-α is a key component of our body’s innate immune response to viral infection. Most cells in the body will produce i...
Product Name : Veldona
Product Type : Large molecule
Upfront Cash : Not Applicable
October 31, 2022
Lead Product(s) : Interferon Alfa
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable